Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer

Clinical significance of different types ofp53gene alteration in surgically treated prostate cancer

(2014) Martina Kluth et al.   INTERNATIONAL JOURNAL OF CANCER

Loss of Cdh1 and Pten Accelerates Cellular Invasiveness and Angiogenesis in the Mouse Uterus1

(2013) Mallory E. Lindberg et al.   BIOLOGY OF REPRODUCTION

Integrative Genomic Analyses Reveal an Androgen-Driven Somatic Alteration Landscape in Early-Onset Prostate Cancer

(2013) Joachim Weischenfeldt et al.   CANCER CELL

CHD1 Is a 5q21 Tumor Suppressor Required for ERG Rearrangement in Prostate Cancer

(2013) L. Burkhardt et al.   CANCER RESEARCH

Punctuated Evolution of Prostate Cancer Genomes

(2013) Sylvan C. Baca et al.   CELL

Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressiveERGfusion-positive prostate cancers

(2013) Antje Krohn et al.   JOURNAL OF PATHOLOGY

Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions

(2013) Martina Kluth et al.   MODERN PATHOLOGY

ReducedWWOXprotein expression in human astrocytoma

(2013) William Winardi et al.   NEUROPATHOLOGY

Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer

(2012) Antje Krohn et al.   AMERICAN JOURNAL OF PATHOLOGY

The expression and significance of WWOX and β-catenin in hepatocellular carcinoma

(2012) Yu-Pu Li et al.   APMIS

The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis

(2012) A. Pettersson et al.   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Next-generation Prostate Cancer Biobanking

(2012) Raquel Esgueva et al.   DIAGNOSTIC MOLECULAR PATHOLOGY

Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity

(2012) Himisha Beltran et al.   EUROPEAN UROLOGY

The mutational landscape of lethal castration-resistant prostate cancer

(2012) Catherine S. Grasso et al.   NATURE

Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer

(2012) Christopher E Barbieri et al.   NATURE GENETICS

ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy

(2011) Sarah Minner et al.   CLINICAL CANCER RESEARCH

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer

(2011) A Marije Hoogland et al.   MODERN PATHOLOGY

Recurrent deletion of CHD1 in prostate cancer with relevance to cell invasiveness

(2011) S Huang et al.   ONCOGENE

Integrative Genomic Profiling of Human Prostate Cancer

(2010) Barry S. Taylor et al.   CANCER CELL

Low Level Her2 Overexpression Is Associated with Rapid Tumor Cell Proliferation and Poor Prognosis in Prostate Cancer

(2010) S. Minner et al.   CLINICAL CANCER RESEARCH

The prognostic significance of WWOX expression in patients with breast cancer and its association with the basal-like phenotype

(2010) Xiao Wang et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Haplo-insufficiency: a driving force in cancer

(2010) Alice H Berger et al.   JOURNAL OF PATHOLOGY

Hochdurchsatz-Sequenzierung von gefrorenem und in Paraffin eingebettetem Tumor- und Normalgewebe

(2010) M. Kerick et al.   PATHOLOGE

Chromosome 8p Deletions and 8q Gains are Associated with Tumor Progression and Poor Prognosis in Prostate Cancer

(2009) A. T. El Gammal et al.   CLINICAL CANCER RESEARCH

Distinct genomic aberrations associated withERGrearranged prostate cancer

(2009) Francesca Demichelis et al.   GENES CHROMOSOMES & CANCER

Induced Chromosomal Proximity and Gene Fusions in Prostate Cancer

(2009) R.-S. Mani et al.   SCIENCE

Cadherins and cancer: how does cadherin dysfunction promote tumor progression?

(2008) A Jeanes et al.   ONCOGENE